Comparison of immune responses induced in mice by vaccination with DNA vaccine constructs expressing mycobacterial antigen 85A and interleukin-21 and bacillus Galmette-Guerin

被引:20
作者
Dou, Jun [1 ]
Tang, Quan [1 ]
Zhao, Fengshu [1 ]
Chu, Lili [1 ]
Chen, Junsong [1 ]
Cao, Minggang [1 ]
Liu, Chunsheng [1 ]
Wang, Yongfang [1 ]
Li, Yating [1 ]
Li, Jin Long [1 ]
机构
[1] SE Univ, Sch Basic Med Sci, Dept Pathogen Biol & Immunol, Nanjing 210009, Peoples R China
关键词
mycobacterium tuberculosis; antigen; 85A; interleukin-21; DNA vaccine; bacillus Galmette-Guerin; immune accessory;
D O I
10.1080/08820130701690741
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In this paper, we addressed the immune adjuvant effects of interleukin(IL)-21 on DNA vaccine constructs expressing mycobacterium tuberculosis (TB) Ag85A and compared immune responses induced in mice inoculated DNA vaccine constructs expressing Ag85A and IL-21 with mice inoculated DNA vaccine constructs expressing Ag85A alone or Bacillus Galmette-Guerin(BCG.). In this experiment, the gene of IL-21 was firstly amplified from plasmid pcDNA3.1-mIL21 by PCR and cloned into the plasmid pRSC, forming recombinant plasmid pRSC-IL21. Then, the gene of Ag85A was amplified from the plasmid pIRES-Ag85A by PCR and cloned into the recombinant pRSC-IL21 again, finally forming co-expression DNA vaccine constructs pRSC-IL21-Ag85A. It was identified by the analysis of endonuclease digestion, DNA sequencing, the IL-21 and Ag85A expression in SP2/0 cells. Mice were i.m. immunized with BCG, DNA vaccine constructs pRSC-Ag85A or pRSC-IL21-Ag85A respectively, and the immune responses induced in mice was compared with other vaccines. The results showed that the DNA vaccine constructs pRSC-IL21-Ag85A was successfully constructed since the Ag85A and IL-21 was correctly expressed in SP2/0 cells respectively, and it elicited stronger immune responses in Balb/c mice than that of mice immunized with pRSC-Ag85A and the efficiency was as BCG did. We concluded that the IL-21 was a promising immune adjunctive modality to enhance immunigenicity of DNA vaccine containing Ag85A and the study provided the possibility of further development of immune accessory effect of IL-21 on DNA vaccine against TB.
引用
收藏
页码:113 / 127
页数:15
相关论文
共 31 条
[1]   Mycobacterium tuberculosis (Mtb) isocitrate dehydrogenases show strong B cell response and distinguish vaccinated controls from TB patients [J].
Banerjee, S ;
Nandyala, A ;
Podili, R ;
Katoch, VM ;
Murthy, KJR ;
Hasnain, SE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (34) :12652-12657
[2]   The growing burden of tuberculosis - Global trends and interactions with the HIV epidemic [J].
Corbett, EL ;
Watt, CJ ;
Walker, N ;
Maher, D ;
Williams, BG ;
Raviglione, MC ;
Dye, C .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (09) :1009-1021
[3]   Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma [J].
Curti, Brendan D. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (06) :905-909
[4]  
de Paula Lucia, 2007, Genet Vaccines Ther, V5, P2, DOI 10.1186/1479-0556-5-2
[5]   Interaction of dendritic cells with mycobacteria: Where the action starts [J].
Demangel, C ;
Britton, WJ .
IMMUNOLOGY AND CELL BIOLOGY, 2000, 78 (04) :318-324
[6]   A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity [J].
Derrick, SC ;
Yang, AL ;
Morris, SL .
VACCINE, 2004, 23 (06) :780-788
[7]   Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity [J].
Dietrich, Jes ;
Andersen, Claire ;
Rappuoli, Rino ;
Doherty, T. Mark ;
Jensen, Charlotte Green ;
Andersen, Peter .
JOURNAL OF IMMUNOLOGY, 2006, 177 (09) :6353-6360
[8]  
Dou J, 2005, CELL MOL IMMUNOL, V2, P57
[9]   Global trends in resistance to antituberculosis drugs [J].
Espinal, MA ;
Laszlo, A ;
Simonsen, L ;
Boulahbal, F ;
Kim, SJ ;
Reniero, A ;
Hoffner, S ;
Rieder, HL ;
Binkin, N ;
Dye, C ;
Williams, R ;
Raviglione, MC .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (17) :1294-1303
[10]  
FORDHAM VR, 2002, VACCINES, V35, P465